Interleukin-6 and Lipopolysaccharide Modulate Hepcidin mRNA Expression by Hepg2 Cells

被引:1
|
作者
Pia Villarroel
Solange Le Blanc
Miguel Arredondo
机构
[1] University of Chile,Micronutrient Laboratory, INTA
来源
关键词
Hepcidin; HepG2 cells; Interleukin-6; Lipopolysaccharide;
D O I
暂无
中图分类号
学科分类号
摘要
Iron homeostasis is controlled by hepcidin (Hpc) as well as other ways. Hpc expression is regulated by iron (Fe) storage and by inflammation, but the joint effect of both stimuli remains unclear. We studied the modulatory role of inflammatory agents (IL6 and LPS) over Hpc and DMT1 mRNA expression in HepG2 cells preloaded with Fe. HepG2 cells were preloaded with different Fe concentrations (holo-Tf or Fe-NTA) and then incubated with IL6 or LPS. We measured intracellular Fe levels by AAS with graphite furnace, transferrin receptor (TfR) by ELISA and mRNA relative abundance of Hpc and DMT1 by qRT-PCR. The maximum effect on Fe uptake was observed in cells incubated with 30 ng/ml IL6 (p < 0.01) and 500 ng/ml LPS (p < 0.05). In HepG2 cells preloaded with holo-Tf or Fe-NTA and challenged with IL6 and LPS, we observed a decreased: (a) Hpc mRNA relative abundance (two-way ANOVA: p < 0.05 and p < 0.001, respectively), (b) DMT1 mRNA relative abundance and TfR1 protein levels (two-way ANOVA: p < 0.001), and (c) intracellular Fe concentration (two-way ANOVA: p < 0.001 and p < 0.01, respectively) compared to control cells incubated only with Fe (holo-Tf or Fe-NTA). Our results support the idea that Fe storage and inflammation act together to regulate Fe homeostasis and suggest a negative regulation in this hepatic cellular model to prevent excessive increases in Hpc.
引用
收藏
页码:496 / 501
页数:5
相关论文
共 50 条
  • [21] THE HUMAN INTER-ALPHA-TRYPSIN INHIBITOR GENES RESPOND DIFFERENTLY TO INTERLEUKIN-6 IN HEPG2 CELLS
    SARAFAN, N
    MARTIN, JP
    BOURGUIGNON, J
    BORGHI, H
    CALLE, A
    SESBOUE, R
    DIARRAMEHRPOUR, M
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 227 (03): : 808 - 815
  • [22] Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-10 and tumor necrosis factor-α, but is upregulated by interleukin-6
    Kumon, Y
    Suehiro, T
    Ikeda, Y
    Hashimoto, K
    LIFE SCIENCES, 2003, 73 (22) : 2807 - 2815
  • [23] Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B
    Wolber, EM
    Jelkmann, W
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (05): : 499 - 506
  • [24] Interleukin-6 and interleukin-6 receptor mRNA expression in rat central nervous system
    Gadient, RA
    Otten, U
    INTERLEUKIN-6 TYPE CYTOKINES, 1995, 762 : 403 - 406
  • [25] SUPPRESSION OF CYTOCHROME P450IA1 BY INTERLEUKIN-6 IN HUMAN HEPG2 HEPATOMA-CELLS
    FUKUDA, Y
    SASSA, S
    BIOCHEMICAL PHARMACOLOGY, 1994, 47 (07) : 1187 - 1195
  • [26] Interleukin 8 response and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde or lipopolysaccharide
    Gómez-Quiroz, L
    Bucio, L
    Souza, V
    Escobar, C
    Farfán, B
    Hernández, E
    Konigsberg, M
    Vargas-Vorakova, F
    Kershenobich, D
    Gutiérrez-Ruiz, C
    HEPATOLOGY RESEARCH, 2003, 26 (02) : 134 - 141
  • [27] Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2)
    Citarella, F
    Felici, A
    Brouwer, M
    Wagstaff, J
    Fantoni, A
    Hack, CE
    BLOOD, 1997, 90 (04) : 1501 - 1507
  • [28] Changes of miRNA and mRNA expression in HepG2 cells treated by epigallocatechin gallate
    Joon-Ik Ahn
    Kyung Ji Jeong
    Moon-Jeong Ko
    Hee Jung Shin
    Hye Soo Kim
    Hye Joo Chung
    Ho-Sang Jeong
    Molecular & Cellular Toxicology, 2010, 6 : 169 - 177
  • [29] Changes of miRNA and mRNA expression in HepG2 cells treated by epigallocatechin gallate
    Ahn, Joon-Ik
    Jeong, Kyung Ji
    Ko, Moon-Jeong
    Shin, Hee Jung
    Kim, Hye Soo
    Chung, Hye Joo
    Jeong, Ho-Sang
    MOLECULAR & CELLULAR TOXICOLOGY, 2010, 6 (02) : 169 - 177
  • [30] Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells
    Haas, MJ
    Wong, NCW
    Mooradian, AD
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (06): : 766 - 771